Toggle navigation
Home
Search
Services
Blog
Contact
About
Development of Effective Spin Traps to Treat Stroke
Maples, Kirk R.
Centaur Pharmaceuticals, Inc., Sunnyvale, CA, United States
Search 9 grants from Kirk Maples
Search grants from Centaur Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Multiscale analysis of tissue macrophage response to CMV
Healthcare utilization patterns and associated costs for Gulf War I Era Veterans
A Prognostic System for Selecting Appropriate Level of Amputation
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS
Transcriptional Control of Cardiac Muscle Development
Recently added grants:
The neural computations supporting hierarchical reinforcement learning
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44NS032597-03
Application #
2037760
Study Section
Special Emphasis Panel (ZRG1-BPO (01))
Program Officer
Jacobs, Tom P
Project Start
1994-02-01
Project End
1997-08-31
Budget Start
1996-09-01
Budget End
1997-08-31
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Centaur Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Sunnyvale
State
CA
Country
United States
Zip Code
94085
Related projects
NIH 1996
R44 NS
Development of Effective Spin Traps to Treat Stroke
Maples, Kirk R. / Centaur Pharmaceuticals, Inc.
NIH 1995
R44 NS
Development of Effective Spin Traps to Treat Stroke
Maples, Kirk R. / Centaur Pharmaceuticals, Inc.
Comments
Be the first to comment on Kirk Maples's grant